Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: AzurRx BioPharma Inc. AZRX

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared key takeaways from its topline results on its Phase 2b OPTION 2 clinical trial. The trial studied AzurRx’s drug … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Upcoming Phase 2b Clinical Trial of Cystic Fibrosis Treatment

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Participation in Emerging Growth Virtual Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual Maxim Group Emerging Growth Virtual Conference. The two-day conference is slated for March 17–18, … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held … Continue reading

Posted in AzurRx BioPharma Inc. AZRX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced the appointment of James Sapirstein, president and CEO, as chairman of the company’s board of directors, effective immediately. … Continue reading

Posted in AzurRx BioPharma Inc. AZRX | Leave a comment